The table below shows Amphastar Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$719.89M
$731.97M
$644.39M
$498.99M
$437.77M
$349.85M
Cost of revenue
$363.83M
$358.11M
$293.27M
$250.13M
$238.03M
$206.51M
Gross profit
$356.06M
$373.86M
$351.12M
$248.86M
$199.74M
$143.34M
R&D
$85.84M
$73.91M
$73.74M
$74.77M
$60.93M
$67.23M
AMPH annual revenue (10-K history)
Amphastar Pharmaceuticals, Inc. reported annual revenue of $719.89M for fiscal year 2025. That is down 1.7% from $731.97M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $255.16M (FY 2016) to $719.89M. Figures come from the company's audited annual reports as filed with the SEC.